Cancer drugs show low risk of postmarket safety events

by ecancer reported Janet Fricker Just under one third of novel therapeutics have been affected by a postmarket safety event by 10 years after Federal Drugs Administration (FDA) approval, finds a US study published in JAMA. Postmarket safety events were...

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2pO05aT
via IFTTT